Archimed takes majority stake in Brazil wastewater treatment firm Genetica Bioscience

Archimed took a majority stake in Genetica Bioscience, a Brazilian provider of bio-based industrial wastewater treatment solutions. Deal completed through Archimed’s MED III fund, with Rise Investment joining as a minority co-investor. Genetica, founded in 2005 and based in Chapecó, also operates in biogas generation and bio-based crop protection. Transaction marks Archimed’s first stand-alone investment in Brazil and the 10th investment from MED III, a €650 million fund closed in 2021. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Archimed SAS published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein. (C)